Drugs / PLB1003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03130881 | Nov 2016 → Dec 2020 | non-small cell lung carcinoma | Beijing Pearl Biotechnology Limited Liability Company | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PLB1003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03130881 ↗ |
| Action | Inhibit | “PLB1003 is a potent selective ALK inhibitor.” NCT03130881 ↗ |
| Route | Oral | “is administered orally” NCT03130881 ↗ |
| Target | ALK | “PLB1003 acts on cancer by blocking abnormal ALK-mediated signaling” NCT03130881 ↗ |